昭栄薬品 [3537]: Notice Concerning the Revision of the Consolidated Earnings Forecast for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027, 18 September 2026 (Timely Disclosure): Nikkei Company Information DIGITAL

The story

昭栄薬品 disclosed its intention to revise its consolidated earnings forecast for the second quarter of the fiscal year ending March 2027.

The text does not provide specific figures for the revision or the level of the new forecast, nor does it mention the revision's effective period or underlying assumptions.

The supporting source is The Nikkei, and the information is presented as reporting by Nikkei.

At a glance

Company昭栄薬品

EventRevision of the earnings forecast for the second quarter of the fiscal year ending March 2027

DateAnnounced on 18 September 2026

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

NikkeiNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.